Iridex (NASDAQ: IRIX; Mountain View, CA) has been awarded a competitive tender for more than $350,000 in ophthalmology laser equipment by the government of Zambia.
Related: Iridex to fill large orders from developing countries for ophthalmic laser systems
Diabetes continues to grow rapidly in many developing parts of the world, and with that comes the spread of related eye diseases such as diabetic macular edema (DME), explains Will Moore, the company's president and CEO. Recognizing that health systems in many countries cannot support the use of injectable drugs for these diseases due to logistics and cost, the company's laser-based treatments are as effective as drugs in terms of long-term outcomes, are much less costly to a healthcare system, and are much easier to administer from a logistics standpoint because they provide durable results, he adds.
Moore adds that the advances in laser therapies are also ushering in a paradigm shift in the U.S. and European ophthalmology markets, including DME and glaucoma treatments, as they achieve durable results against their progression without harming healthy tissue.
-----
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!